financetom
Business
financetom
/
Business
/
Donnelley Financial Solutions Q4 Adjusted Earnings, Net Sales Fall -- Shares Rise Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Donnelley Financial Solutions Q4 Adjusted Earnings, Net Sales Fall -- Shares Rise Pre-Bell
Feb 18, 2025 4:52 AM

07:26 AM EST, 02/18/2025 (MT Newswires) -- Donnelley Financial Solutions ( DFIN ) reported Q4 adjusted net earnings Tuesday of $0.40 per diluted share, down from $0.61 a year earlier.

Three analysts surveyed by FactSet expected $0.49.

Net sales for the quarter ended Dec. 31 was $156.3 million, down from $176.5 million a year earlier. Three analysts surveyed by FactSet expected $169.2 million.

Donnelley shares were up nearly 6% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Garmin's Fiscal Q3 Adjusted Earnings Flat, Revenue Rises; Fiscal 2025 Adjusted EPS Guidance Raised
Garmin's Fiscal Q3 Adjusted Earnings Flat, Revenue Rises; Fiscal 2025 Adjusted EPS Guidance Raised
Oct 29, 2025
07:31 AM EDT, 10/29/2025 (MT Newswires) -- Garmin ( GRMN ) reported fiscal Q3 adjusted earnings Wednesday of $1.99 per diluted share, unchanged from a year earlier. Analysts polled by FactSet expected $1.99. Net sales for the fiscal quarter ended Sept. 27 were $1.77 billion, up from $1.59 billion a year earlier. Analysts polled by FactSet expected $1.78 billion. The...
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
Oct 29, 2025
On Wednesday, Anavex Life Sciences Corp. ( AVXL ) announced new findings for blarcamesine, an oral small molecule for early Alzheimer's disease. AVXL stock is taking a breather. Get the market research here. New data demonstrate continued long-term benefit from oral blarcamesine compared to the decline observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) control group. Data Externally matched control...
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
Oct 29, 2025
On Wednesday, Anavex Life Sciences Corp. ( AVXL ) announced new findings for blarcamesine, an oral small molecule for early Alzheimer's disease. AVXL stock is taking a breather. Get the market research here. New data demonstrate continued long-term benefit from oral blarcamesine compared to the decline observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) control group. Data Externally matched control...
Fiserv Q3 Adjusted Earnings Fall, Revenue Rises; 2025 Adjusted Earnings and Organic Revenue Guidance Lowered
Fiserv Q3 Adjusted Earnings Fall, Revenue Rises; 2025 Adjusted Earnings and Organic Revenue Guidance Lowered
Oct 29, 2025
07:30 AM EDT, 10/29/2025 (MT Newswires) -- Fiserv ( FI ) reported Q3 adjusted earnings Wednesday of $2.04 per share, down from $2.30 a year earlier. Analysts polled by FactSet expected $2.64. Revenue for the quarter ended Sept. 30 was $5.26 billion, compared with $5.22 billion a year earlier. Analysts surveyed by FactSet expected $5.35 billion. For 2025, the financial...
Copyright 2023-2026 - www.financetom.com All Rights Reserved